M. V. Orobei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
M. V. Orobei has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Julia S. Kovaleva
Altai State Medical University
6 shared publications - N. K. Zyablitskaya
Altai State Medical University
6 shared publications - R. E. Goltsov
Altai State Medical University
3 shared publications - Natal'YA K. Bishevskaya
Altay State Medical University
2 shared publications - A. G. Petrova
Detskiy Doktor Clinic
1 shared publication - P. D. Savelyeva
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication
Latest Publications
- Open Access
- 10 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 81-93
Synthetic tannin and polidocanol in topical therapy of allergic dermatoses in children
Allergic skin diseases in young children are characterized by pronounced exudation due to anatomical immaturity of the skin, increased vascular permeability, spongiosis, and a disrupted epidermal barrier. This article describes in detail the mechanisms of immune inflammation, in which proinflammatory mediators (histamine, IL-4, IL-13, etc.) play a key role, as well as chronic itching and scratching, which creating a vicious cycle of “itching – scratching – inflammation”. The pathogenesis of exacerbations with oozing and exudation is discussed. Allergic skin diseases hold a leading place in the structure of childhood skin pathology, and the features of their course at this age – a tendency to exudation, involvement of sensitive areas, and a high risk of secondary infection – impose special requirements on topical agents, whose safety is no less important than efficacy. The properties of synthetic tannin and polidocanol, the basis of Neotanin – a barrier agent approved for use in children from the first month of life, free of hormones, antibiotics, and dyes, and acting within the stratum corneum without systemic absorption – are considered. Synthetic tannin forms a protective film on the skin surface, exerts astringent, drying, and antipruritic effects, and prevents secondary infection, while polidocanol additionally reduces itching. The authors present three clinical cases of successful treatment of allergic dermatoses in children with Neotanin – both in various combinations with topical glucocorticosteroids and as monotherapy, including lesions localized on sensitive skin areas. In all observations, regression of inflammation and relief of itching were achieved, and no adverse events were recorded.
- 10 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 81-93
Open AccessSynthetic tannin and polidocanol in topical therapy of allergic dermatoses in children
Allergic skin diseases in young children are characterized by pronounced exudation due to anatomical immaturity of the skin, increased vascular permeability, spongiosis, and a disrupted epidermal barrier. This article describes in detail the mechanisms of immune inflammation, in which proinflammatory mediators (histamine, IL-4, IL-13, etc.) play a key role, as well as chronic itching and scratching, which creating a vicious cycle of “itching – scratching – inflammation”. The pathogenesis of exacerbations with oozing and exudation is discussed. Allergic skin diseases hold a leading place in the structure of childhood skin pathology, and the features of their course at this age – a tendency to exudation, involvement of sensitive areas, and a high risk of secondary infection – impose special requirements on topical agents, whose safety is no less important than efficacy. The properties of synthetic tannin and polidocanol, the basis of Neotanin – a barrier agent approved for use in children from the first month of life, free of hormones, antibiotics, and dyes, and acting within the stratum corneum without systemic absorption – are considered. Synthetic tannin forms a protective film on the skin surface, exerts astringent, drying, and antipruritic effects, and prevents secondary infection, while polidocanol additionally reduces itching. The authors present three clinical cases of successful treatment of allergic dermatoses in children with Neotanin – both in various combinations with topical glucocorticosteroids and as monotherapy, including lesions localized on sensitive skin areas. In all observations, regression of inflammation and relief of itching were achieved, and no adverse events were recorded.
- 16 April 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 2,p. 80-90
Combination therapy of cutaneous candidiasis in patients with concomitant systemic pathology
Candida fungus is an integral part of the normal human microbiome, but disruption of skin integrity and malperformance of immune function can transform it into a pathogenic form. Some Candida strains are capable of modulating the immune response through suppressing the production of proinflammatory cytokines and inducing T-helper differentiation toward a Th2 response, which contributes to the chronification of inflammation. In this article, we take a detailed look at exogenous and endogenous risk factors. Particular focus has been placed on comorbidities: the present-date knowledge on the role of Candida spp. in exacerbating the course of atopic dermatitis and psoriasis is provided. The authors presented clinical case reports of candidiasis treatment in patients with aggravated histories. Case report 1: a 19-year-old man with complaints of pain, redness, and swelling in the periungual fold area combined with changes in the color and texture of the nail plate. Diagnosis: Periungual fold candidiasis. Onychomycosis. Treatment with 2% sertaconazole cream was prescribed. After 4 weeks, clinical regression of the inflammation process and partial restoration of the nail plate structure was observed. Case report 2: a 37-year-old man with complaints of severe itching, burning, and redness in the groin folds. Diagnosis: Candidal intertrigo of the groin folds associated with antibiotic therapy due to obesity. The prescribed stepwise therapy included: 0.05% clotrimazole + 0.1% gentamicin + 1% betamethasone for 7 days, then 2% sertaconazole cream for 2 weeks. After a three-week therapy, the rash regressed and post-inflammatory hyperpigmentation developed in a patient. Case report 3: a 58-year-old woman with complains of intense itching, burning, pain, and oozing in the abdominal fold within 3 weeks. The patient's medical history told a story of chronic illness. Diagnosis: Candidal intertrigo. The prescribed stepwise therapy included: 0.05% clotrimazole + 0.1% gentamicin + 1% betamethasone for 7 days, then 2% sertaconazole cream for 2 weeks. After a three-week course of treatment, the inflammation regressed. In all cases, skin scrapings showed negative follow-up microscopic examination results.
- 16 April 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 2,p. 80-90
Combination therapy of cutaneous candidiasis in patients with concomitant systemic pathology
Candida fungus is an integral part of the normal human microbiome, but disruption of skin integrity and malperformance of immune function can transform it into a pathogenic form. Some Candida strains are capable of modulating the immune response through suppressing the production of proinflammatory cytokines and inducing T-helper differentiation toward a Th2 response, which contributes to the chronification of inflammation. In this article, we take a detailed look at exogenous and endogenous risk factors. Particular focus has been placed on comorbidities: the present-date knowledge on the role of Candida spp. in exacerbating the course of atopic dermatitis and psoriasis is provided. The authors presented clinical case reports of candidiasis treatment in patients with aggravated histories. Case report 1: a 19-year-old man with complaints of pain, redness, and swelling in the periungual fold area combined with changes in the color and texture of the nail plate. Diagnosis: Periungual fold candidiasis. Onychomycosis. Treatment with 2% sertaconazole cream was prescribed. After 4 weeks, clinical regression of the inflammation process and partial restoration of the nail plate structure was observed. Case report 2: a 37-year-old man with complaints of severe itching, burning, and redness in the groin folds. Diagnosis: Candidal intertrigo of the groin folds associated with antibiotic therapy due to obesity. The prescribed stepwise therapy included: 0.05% clotrimazole + 0.1% gentamicin + 1% betamethasone for 7 days, then 2% sertaconazole cream for 2 weeks. After a three-week therapy, the rash regressed and post-inflammatory hyperpigmentation developed in a patient. Case report 3: a 58-year-old woman with complains of intense itching, burning, pain, and oozing in the abdominal fold within 3 weeks. The patient's medical history told a story of chronic illness. Diagnosis: Candidal intertrigo. The prescribed stepwise therapy included: 0.05% clotrimazole + 0.1% gentamicin + 1% betamethasone for 7 days, then 2% sertaconazole cream for 2 weeks. After a three-week course of treatment, the inflammation regressed. In all cases, skin scrapings showed negative follow-up microscopic examination results.
- Open Access
- 15 September 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 152-162
Allergic contact dermatitis in the beauty industry
Allergic contact dermatitis in the beauty industry is a common and growing problem in dermatology, due to both the annual increase in the popularity of existing beauty services and the emergence of new fashion trends. Cosmetic products in hairdressing, manicure, permanent makeup, eyelash extensions, tattooing and piercing contain a number of potent haptens, sensitization to which results in a classic delayed-type hypersensitivity reaction. The development of contact allergic reactions is important not only for consumers of these services, but also for hairdressers and beauty salon technicians themselves. Thus, hairdressers take first place in the incidence statistics of occupational contact dermatitis associated with allergens and haptens in hair dyes, products for bleaching, curling or straightening hair. In 65% of cases, allergic contact dermatitis to acrylates develops among manicurists within the first years of work. The basis of treatment for allergic contact dermatitis is external therapy using topical glucocorticosteroids. The article contains Russian and foreign literature data about the most common allergens in products used in hairdressing, permanent tattooing, eyelash extensions, manicure and piercing, on the prevalence and characteristics of allergic contact dermatitis in these areas of the beauty industry and our own clinical observations of the effectiveness of treatment of allergic contact dermatitis using Comfoderm K cream (methylprednisolone aceponate with ceramides in the base).
- 15 September 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 152-162
Open AccessAllergic contact dermatitis in the beauty industry
Allergic contact dermatitis in the beauty industry is a common and growing problem in dermatology, due to both the annual increase in the popularity of existing beauty services and the emergence of new fashion trends. Cosmetic products in hairdressing, manicure, permanent makeup, eyelash extensions, tattooing and piercing contain a number of potent haptens, sensitization to which results in a classic delayed-type hypersensitivity reaction. The development of contact allergic reactions is important not only for consumers of these services, but also for hairdressers and beauty salon technicians themselves. Thus, hairdressers take first place in the incidence statistics of occupational contact dermatitis associated with allergens and haptens in hair dyes, products for bleaching, curling or straightening hair. In 65% of cases, allergic contact dermatitis to acrylates develops among manicurists within the first years of work. The basis of treatment for allergic contact dermatitis is external therapy using topical glucocorticosteroids. The article contains Russian and foreign literature data about the most common allergens in products used in hairdressing, permanent tattooing, eyelash extensions, manicure and piercing, on the prevalence and characteristics of allergic contact dermatitis in these areas of the beauty industry and our own clinical observations of the effectiveness of treatment of allergic contact dermatitis using Comfoderm K cream (methylprednisolone aceponate with ceramides in the base).
- Open Access
- 12 March 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 103-110
Selective reversible JAK1 inhibitor in the treatment of moderate and severe atopic dermatitis
In recent decades, industrialized countries have recorded a steady increase in the incidence of atopic dermatitis (AD). The pathogenesis of AD is complex and diverse and includes hereditary determinism leading to a disruption of the skin barrier, as well as the Th2 immune response, which is supported by a wide range of pro-inflammatory mediators released by immunocompetent and epithelial cells, which play a key role in the activation and maintenance of inflammation in the skin. Progress in the treatment of immunoinflammatory diseases, including in the skin, has been achieved with the advent of a new class of targeted synthetic oral immunomodulatory drugs, Janus kinase inhibitors. Janus kinases are part of the JAK – STAT intracellular signaling system; STAT proteins are responsible for signaling more than 60 cytokines, hormones and growth factors that regulate key cellular processes. Currently, second generation JAK inhibitors have been developed, such as upadacitinib (trade name Rinvoq), which distinguish them from non-selective JAK inhibitors by their selectivity for certain JAK isoforms. In June 2021, the Ministry of Health of the Russian Federation approved the use of upadacitinib (UPA) for the indication “treatment of moderate to severe atopic dermatitis in adults and children aged 12 years and older who are indicated for treatment with systemic drugs”; the drug can be used in monotherapy or in combination with topical therapy in adults at a dose of 15 or 30 mg per day depending on the individual characteristics of the course, in adolescents weighing at least 40 kg – at a dose of 15 mg per day. Results from a Phase 3 clinical trial program involving more than 2500 patients worldwide in three global key studies: Measure Up 1, Measure Up 2 (UPA monotherapy at a dose of 15 mg or 30 mg per day) and AD Up (UPA in the same doses in combination with topical glucocorticosteroids (TGCS) demonstrated high efficacy and favorable benefit/risk profile of UPA both in monotherapy and in combination with TGCS in patients with moderate to severe AD.
- 12 March 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 103-110
Open AccessSelective reversible JAK1 inhibitor in the treatment of moderate and severe atopic dermatitis
In recent decades, industrialized countries have recorded a steady increase in the incidence of atopic dermatitis (AD). The pathogenesis of AD is complex and diverse and includes hereditary determinism leading to a disruption of the skin barrier, as well as the Th2 immune response, which is supported by a wide range of pro-inflammatory mediators released by immunocompetent and epithelial cells, which play a key role in the activation and maintenance of inflammation in the skin. Progress in the treatment of immunoinflammatory diseases, including in the skin, has been achieved with the advent of a new class of targeted synthetic oral immunomodulatory drugs, Janus kinase inhibitors. Janus kinases are part of the JAK – STAT intracellular signaling system; STAT proteins are responsible for signaling more than 60 cytokines, hormones and growth factors that regulate key cellular processes. Currently, second generation JAK inhibitors have been developed, such as upadacitinib (trade name Rinvoq), which distinguish them from non-selective JAK inhibitors by their selectivity for certain JAK isoforms. In June 2021, the Ministry of Health of the Russian Federation approved the use of upadacitinib (UPA) for the indication “treatment of moderate to severe atopic dermatitis in adults and children aged 12 years and older who are indicated for treatment with systemic drugs”; the drug can be used in monotherapy or in combination with topical therapy in adults at a dose of 15 or 30 mg per day depending on the individual characteristics of the course, in adolescents weighing at least 40 kg – at a dose of 15 mg per day. Results from a Phase 3 clinical trial program involving more than 2500 patients worldwide in three global key studies: Measure Up 1, Measure Up 2 (UPA monotherapy at a dose of 15 mg or 30 mg per day) and AD Up (UPA in the same doses in combination with topical glucocorticosteroids (TGCS) demonstrated high efficacy and favorable benefit/risk profile of UPA both in monotherapy and in combination with TGCS in patients with moderate to severe AD.
- Open Access
- 1 November 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 17,p. 192-202
Topical therapy of dermatoses in children with complex localizations
The skin of children has its own anatomical and physiological characteristics, the epidermis is much thinner than in adults, the layers of the dermis and basement membrane are poorly developed and differentiated, the rate of transepidermal water loss is increased and the level of natural moisturizing factor (NMF) is reduced. Such a structure of the skin predisposes to a violation of its barrier function, contributes to the occurrence of skin diseases, provides an increased resorptive capacity of the skin and requires special attention when prescribing external therapy. The use of high-quality emollients is an important part of the basic treatment of chronic dermatoses and has its own characteristics in childhood. The use of emollients prevents the development of exacerbations and reduces the need for anti-inflammatory topical drugs. With the localization of the inflammatory process on the face, neck, genitals and large folds, it is necessary to give preference to short courses of topical glucocorticosteroids (THCS) with sufficient anti-inflammatory activity, rapid onset of action, minimal side effects. Given the high risk of side effects in children in these areas of the skin, strong fluorinated THCS, high-potency THCS, and the use of THCS under occlusive dressings are not recommended. The Russian experience of using 0.1% methylprednisolone aceponate in children of various age groups in the treatment of allergic dermatoses, including those with localization in sensitive areas, has shown good efficacy, tolerance and the absence of side effects. he article presents own clinical observations of the effectiveness of the use of combination therapy: an emollient agent - a special cream with physiological lipids omega 3-6-9 and cream methylprednisolone aceponate (with ceramides in the base) in the treatment of skin diseases in children with an emphasis on complex localizations, such as face, folds, genital area.
- 1 November 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 17,p. 192-202
Open AccessTopical therapy of dermatoses in children with complex localizations
The skin of children has its own anatomical and physiological characteristics, the epidermis is much thinner than in adults, the layers of the dermis and basement membrane are poorly developed and differentiated, the rate of transepidermal water loss is increased and the level of natural moisturizing factor (NMF) is reduced. Such a structure of the skin predisposes to a violation of its barrier function, contributes to the occurrence of skin diseases, provides an increased resorptive capacity of the skin and requires special attention when prescribing external therapy. The use of high-quality emollients is an important part of the basic treatment of chronic dermatoses and has its own characteristics in childhood. The use of emollients prevents the development of exacerbations and reduces the need for anti-inflammatory topical drugs. With the localization of the inflammatory process on the face, neck, genitals and large folds, it is necessary to give preference to short courses of topical glucocorticosteroids (THCS) with sufficient anti-inflammatory activity, rapid onset of action, minimal side effects. Given the high risk of side effects in children in these areas of the skin, strong fluorinated THCS, high-potency THCS, and the use of THCS under occlusive dressings are not recommended. The Russian experience of using 0.1% methylprednisolone aceponate in children of various age groups in the treatment of allergic dermatoses, including those with localization in sensitive areas, has shown good efficacy, tolerance and the absence of side effects. he article presents own clinical observations of the effectiveness of the use of combination therapy: an emollient agent - a special cream with physiological lipids omega 3-6-9 and cream methylprednisolone aceponate (with ceramides in the base) in the treatment of skin diseases in children with an emphasis on complex localizations, such as face, folds, genital area.
- Open Access
- 7 June 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 8,p. 28-38
Combined pathogenetic therapy of allergic dermatoses in children
Allergodermatoses make up the majority of allergic skin diseases in childhood, have a recurrent course and significantly disrupt the quality of life of patients and their families. The constant use of emollients, allowing to lengthen periods of remission and reduce the need for topical drugs, is associated with defects in the skin barrier function. Treatment with topical glucocorticosteroids (TCS) and topical calcineurin inhibitors (TCI), which are the basis of pharmacotherapy, should be carried out differentially, taking into account the localization, stage and activity of the inflammatory process, the area of the lesion, the age of the child and the multifactorial genesis of the disease. The basic principles of rational local therapy include the choice of the degree of activity of the drug, its concentration, dosage form, dosage frequency, duration of use to obtain a therapeutic effect and minimize side effects. In case of severe exacerbation and localization of inflammatory elements on the body and limbs in children, it is necessary to start treatment with class 2–3 THCS. When the process is localized on the face and other sensitive areas of the skin (neck and large folds), it is recommended to use class 7 TCS or give preference to TCI. The duration of a continuous course of TCS therapy in children depends on the severity of the exacerbation and should not exceed 2 weeks. The most effective way to reduce the course steroid load and avoid side effects is the early and correct use of TCS during an exacerbation. The advantages of TCI in comparison with TCS are the low incidence of side effects, the absence of contraindications for use on sensitive skin areas, and the possibility of longer use. The article contains Russian and foreign literature data on the use of THCS and TEC in the treatment of allegodermatosis in children and our own clinical observations of the effectiveness of the use of combination therapy: Comfoderm K cream (methylprednisolone aceponate with ceramides in the base), 0.03% tacrolimus ointment and emollient means - special cream Sensoderm with physiological lipids omega 3–6–9.
- 7 June 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 8,p. 28-38
Open AccessCombined pathogenetic therapy of allergic dermatoses in children
Allergodermatoses make up the majority of allergic skin diseases in childhood, have a recurrent course and significantly disrupt the quality of life of patients and their families. The constant use of emollients, allowing to lengthen periods of remission and reduce the need for topical drugs, is associated with defects in the skin barrier function. Treatment with topical glucocorticosteroids (TCS) and topical calcineurin inhibitors (TCI), which are the basis of pharmacotherapy, should be carried out differentially, taking into account the localization, stage and activity of the inflammatory process, the area of the lesion, the age of the child and the multifactorial genesis of the disease. The basic principles of rational local therapy include the choice of the degree of activity of the drug, its concentration, dosage form, dosage frequency, duration of use to obtain a therapeutic effect and minimize side effects. In case of severe exacerbation and localization of inflammatory elements on the body and limbs in children, it is necessary to start treatment with class 2–3 THCS. When the process is localized on the face and other sensitive areas of the skin (neck and large folds), it is recommended to use class 7 TCS or give preference to TCI. The duration of a continuous course of TCS therapy in children depends on the severity of the exacerbation and should not exceed 2 weeks. The most effective way to reduce the course steroid load and avoid side effects is the early and correct use of TCS during an exacerbation. The advantages of TCI in comparison with TCS are the low incidence of side effects, the absence of contraindications for use on sensitive skin areas, and the possibility of longer use. The article contains Russian and foreign literature data on the use of THCS and TEC in the treatment of allegodermatosis in children and our own clinical observations of the effectiveness of the use of combination therapy: Comfoderm K cream (methylprednisolone aceponate with ceramides in the base), 0.03% tacrolimus ointment and emollient means - special cream Sensoderm with physiological lipids omega 3–6–9.